Madrigal Pharmaceuticals, Inc.
MDGL•NASDAQ•Healthcare•Biotechnology

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOWilliam Sibold
Founded2011
Employees528
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.madrigalpharma.com
Phone267 824 2827
Address
Four Tower Bridge, Suite 200 West Conshohocken, Pennsylvania 19428 United States

Corporate Identifiers

CIK0001157601
CUSIP558868105
ISINUS5588681057
SIC2834

Leadership Team & Key Executives

William J. Sibold
Chief Executive Officer, President and Director
Dr. Rebecca A. Taub M.D.
Founder, Senior Scientific and Medical Advisor and Director
Mardi C. Dier
Executive Vice President and Chief Financial Officer
Shannon Kelley
Executive Vice President, Chief Legal Officer and Corporate Secretary
Carole Huntsman
Executive Vice President and Chief Commercial Officer
Mark Underwood
Executive Vice President of Business Planning and Operations
Ronald Filippo
Executive Vice President and Chief Information Officer
Tina E. Ventura
Chief Investor Relations Officer
Clint Wallace
Executive Vice President and Chief Human Resources Officer
Edward Chiang
Senior Vice President of Clinical and Technical Operations